The results of Kong et al (22) suggested that the increased mutation rate of BRCA2 increased the susceptibility to breast, ovarian and prostate cancer, which indicates that that BRCA2 is involved in the development of cancer cells in patients with MC, and has some value in the monitoring of MC. This evidence concerns the gene BRCA2 and prostate cancer.